The pharmaceutical industry faces unprecedented challenges in drug discovery and development, including escalating costs, lengthy timelines, and high attrition rates that threaten global health innovation. Traditional approaches to therapeutic development often require over a decade and billions of dollars in investment, with success rates remaining alarmingly low across all stages of development. This article aims to examine contemporary advances in drug discovery and development, focusing on innovative strategies that have emerged to address these fundamental challenges. Key methodologies including high-throughput screening technologies, advanced target identification and validation platforms, and systematic lead optimization approaches have revolutionized early-stage discovery processes. The integration of computational tools, artificial intelligence algorithms, and omics technologies has enabled more precise target selection and accelerated compound optimization. Translational strategies bridging preclinical models and clinical applications have improved predictive validity and reduced late-stage failures. These innovations have collectively shortened development timelines, enhanced success rates, and enabled more cost-effective pathways to therapeutic approval. Furthermore, precision medicine approaches and biomarker-guided development have facilitated patient stratification and personalized treatment strategies. The convergence of technological advancement, regulatory adaptation, and collaborative research models promises to accelerate therapeutic innovation while addressing critical global health needs, including neglected diseases and emerging pandemic threats. Future directions emphasize sustainable innovation ecosystems that balance efficiency, safety, and equitable access to transformative medicines.